<!doctype html>
<html lang="en">
  <head>
    <meta charset="UTF-8" />
    <meta name="viewport" content="width=device-width, initial-scale=1.0" />
    <title>Pituitary Disorders - Clinical Study Note</title>
    <link rel="icon" type="image/png" sizes="48x48" href="/icons/favicon-48.png?v=20260227-favicon1" />
    <link rel="icon" type="image/png" sizes="32x32" href="/icons/favicon-32.png?v=20260227-favicon1" />
    <link rel="icon" type="image/png" sizes="16x16" href="/icons/favicon-16.png?v=20260227-favicon1" />
    <link rel="apple-touch-icon" sizes="180x180" href="/icons/favicon-180.png?v=20260227-favicon1" />
    <style>
      :root {
        --bg: #f8fbff;
        --surface: #ffffff;
        --ink: #132841;
        --muted: #556c84;
        --line: #d7e4f0;
        --brand: #36407e;
        --brand-soft: #eff1ff;
        --teal-soft: #eefaf6;
        --warn-soft: #fff7e8;
        --danger-soft: #fff0f0;
      }

      * {
        box-sizing: border-box;
      }

      body {
        margin: 0;
        font-family: "Segoe UI", Tahoma, Arial, sans-serif;
        color: var(--ink);
        background:
          radial-gradient(circle at 84% 8%, #dbddff 0%, transparent 31%),
          radial-gradient(circle at 10% 20%, #e8f5ff 0%, transparent 24%),
          var(--bg);
      }

      .wrap {
        width: min(1240px, 94vw);
        margin: 22px auto 34px;
        display: grid;
        grid-template-columns: 290px 1fr;
        gap: 16px;
      }

      .panel {
        background: var(--surface);
        border: 1px solid var(--line);
        border-radius: 16px;
        box-shadow: 0 10px 24px rgba(13, 34, 62, 0.06);
      }

      .toc {
        position: sticky;
        top: 16px;
        max-height: calc(100dvh - 32px);
        overflow: auto;
        padding: 14px;
      }

      .toc h2 {
        margin: 0 0 10px;
        color: var(--brand);
        font-size: 1rem;
      }

      .toc a {
        display: block;
        text-decoration: none;
        color: #36506c;
        border-radius: 8px;
        padding: 7px 9px;
        font-size: 13px;
      }

      .toc a:hover {
        background: #f1f2ff;
        color: #36407e;
      }

      .content {
        padding: 0 0 18px;
      }

      .hero {
        padding: 20px;
        border-bottom: 1px solid var(--line);
        background: linear-gradient(160deg, #ffffff 0%, #f1f2ff 56%, #eef7ff 100%);
      }

      .eyebrow {
        display: inline-flex;
        align-items: center;
        min-height: 28px;
        padding: 5px 12px;
        border-radius: 999px;
        background: var(--brand-soft);
        color: #36407e;
        font-size: 12px;
        font-weight: 700;
        margin-bottom: 10px;
      }

      h1 {
        margin: 0;
        color: #2f376e;
        font-size: clamp(1.42rem, 2.4vw, 2.04rem);
      }

      .subtitle {
        margin: 8px 0 0;
        color: var(--muted);
        line-height: 1.55;
      }

      .hero-layout {
        margin-top: 14px;
        display: grid;
        grid-template-columns: 1.35fr 0.95fr;
        gap: 12px;
      }

      .hero-grid {
        display: grid;
        grid-template-columns: repeat(4, minmax(0, 1fr));
        gap: 10px;
      }

      .metric {
        border: 1px solid #dde0f6;
        border-radius: 12px;
        background: #fff;
        padding: 10px;
      }

      .metric .k {
        font-size: 11px;
        color: #666e8b;
        margin-bottom: 6px;
        text-transform: uppercase;
        letter-spacing: 0.3px;
      }

      .metric .v {
        font-size: 14px;
        color: #2f376e;
        font-weight: 700;
      }

      .hero-visual {
        border: 1px solid #dde0f6;
        border-radius: 14px;
        background: #fff;
        padding: 10px;
        display: grid;
        gap: 8px;
      }

      .hero-visual h3 {
        margin: 0;
        font-size: 0.95rem;
        color: #2f376e;
      }

      .hero-visual p {
        margin: 0;
        font-size: 0.84rem;
        color: #5d758c;
      }

      .hero-visual svg {
        width: 100%;
        height: auto;
        display: block;
      }

      .section {
        padding: 16px 20px;
        border-bottom: 1px solid #edf3fb;
      }

      .section:last-child {
        border-bottom: none;
      }

      .section h2 {
        margin: 0 0 10px;
        color: #2f376e;
        font-size: 1.16rem;
      }

      .section p {
        margin: 0;
        color: #314860;
        line-height: 1.56;
      }

      .stack {
        margin-top: 10px;
        display: grid;
        gap: 10px;
      }

      .grid-2 {
        display: grid;
        grid-template-columns: repeat(2, minmax(0, 1fr));
        gap: 10px;
      }

      .grid-3 {
        display: grid;
        grid-template-columns: repeat(3, minmax(0, 1fr));
        gap: 10px;
      }

      .box {
        border: 1px solid var(--line);
        border-radius: 12px;
        padding: 11px 12px;
        background: #fff;
      }

      .box h3 {
        margin: 0 0 7px;
        font-size: 0.97rem;
        color: #1f4061;
      }

      .box p {
        margin: 0;
      }

      .box ul {
        margin: 0 0 0 17px;
        padding: 0;
      }

      .box li {
        margin: 4px 0;
        color: #304860;
      }

      .table {
        margin-top: 8px;
        width: 100%;
        border-collapse: collapse;
        border-radius: 12px;
        border: 1px solid var(--line);
        overflow: hidden;
      }

      .table th,
      .table td {
        padding: 10px;
        text-align: left;
        font-size: 14px;
        border-bottom: 1px solid #e8eff8;
        vertical-align: top;
      }

      .table th {
        background: #f3f4ff;
        color: #2f376e;
      }

      .table tr:last-child td {
        border-bottom: none;
      }

      .chips {
        margin-top: 8px;
        display: flex;
        gap: 8px;
        flex-wrap: wrap;
      }

      .chip {
        display: inline-flex;
        align-items: center;
        min-height: 30px;
        padding: 4px 10px;
        border-radius: 999px;
        border: 1px solid #d8e4f2;
        background: #f8fbff;
        color: #254764;
        font-size: 13px;
        font-weight: 600;
      }

      .callout {
        margin-top: 10px;
        border-left: 4px solid #0f766e;
        border-radius: 10px;
        background: var(--teal-soft);
        color: #175358;
        padding: 10px 12px;
      }

      .callout.warn {
        border-left-color: #b66a00;
        background: var(--warn-soft);
        color: #7c5b1d;
      }

      .callout.alert {
        border-left-color: #b91c1c;
        background: var(--danger-soft);
        color: #6d2222;
      }

      .flow {
        margin-top: 10px;
        display: grid;
        gap: 9px;
      }

      .step {
        border: 1px solid #d5e3f4;
        border-radius: 12px;
        padding: 10px 11px;
        background: #f9fcff;
      }

      .step strong {
        color: #2f376e;
      }

      .arrow {
        width: 30px;
        height: 30px;
        margin: 0 auto;
        border-radius: 999px;
        border: 1px solid #c9d8ec;
        background: #f6fbff;
        color: #456887;
        font-weight: 900;
        display: grid;
        place-items: center;
        line-height: 1;
      }

      .diagram-card {
        margin-top: 10px;
        border: 1px solid #d8e4f2;
        border-radius: 12px;
        background: #fbfdff;
        padding: 11px;
      }

      .diagram-title {
        margin: 0 0 8px;
        font-size: 0.9rem;
        color: #1d3f62;
        font-weight: 700;
      }

      .refs a {
        color: #145aa9;
        text-decoration: none;
        word-break: break-word;
      }

      .refs a:hover {
        text-decoration: underline;
      }

      @media (max-width: 1040px) {
        .wrap {
          grid-template-columns: 1fr;
        }

        .toc {
          position: static;
          max-height: none;
        }

        .hero-layout {
          grid-template-columns: 1fr;
        }

        .hero-grid {
          grid-template-columns: repeat(2, minmax(0, 1fr));
        }
      }

      @media (max-width: 760px) {
        .grid-2,
        .grid-3,
        .hero-grid {
          grid-template-columns: 1fr;
        }
      }
    </style>
  </head>
  <body>
    <div class="wrap">
      <aside class="panel toc">
        <h2>On This Page</h2>
        <a href="#pituitary-physiology">1. Pituitary Physiology</a>
        <a href="#prolactinoma">2. Prolactinoma</a>
        <a href="#acromegaly">3. Acromegaly</a>
        <a href="#diabetes-insipidus">4. Diabetes Insipidus</a>
        <a href="#siadh">5. SIADH</a>
        <a href="#management-recap-drill">Recap Drill</a>
        <a href="#exam-traps">6. Common Exam Traps</a>
        <a href="#quick-revision">7. Quick Revision Summary</a>
      </aside>

      <article class="panel content">
        <header class="hero">
          <span class="eyebrow">Endocrinology</span>
          <h1>Pituitary Disorders</h1>
          <p class="subtitle">
            Clinical overview and exam mastery guide for prolactinoma, acromegaly,
            diabetes insipidus, and SIADH with pathway-directed pharmacology.
          </p>

          <div class="hero-layout">
            <div class="hero-grid">
              <div class="metric">
                <div class="k">Most Common Adenoma</div>
                <div class="v">Prolactinoma</div>
              </div>
              <div class="metric">
                <div class="k">Acromegaly First-Line</div>
                <div class="v">Surgery</div>
              </div>
              <div class="metric">
                <div class="k">Central DI</div>
                <div class="v">Desmopressin</div>
              </div>
              <div class="metric">
                <div class="k">SIADH</div>
                <div class="v">Fluid restriction first</div>
              </div>
            </div>

            <div class="hero-visual">
              <h3>Pituitary High-Yield Branches</h3>
              <svg viewBox="0 0 500 220" role="img" aria-label="Pituitary disorders overview">
                <rect x="0" y="0" width="500" height="220" rx="14" fill="#fbfdff" />
                <rect x="20" y="30" width="146" height="72" rx="10" fill="#f3f4ff" stroke="#dde0f6" />
                <text x="93" y="54" text-anchor="middle" font-size="13" fill="#2f376e" font-weight="700">Anterior</text>
                <text x="93" y="72" text-anchor="middle" font-size="12" fill="#6a7190">Prolactin</text>
                <text x="93" y="88" text-anchor="middle" font-size="12" fill="#6a7190">GH/ACTH/TSH/LH/FSH</text>

                <rect x="176" y="30" width="146" height="72" rx="10" fill="#eef7ff" stroke="#d8e6f6" />
                <text x="249" y="54" text-anchor="middle" font-size="13" fill="#1f4467" font-weight="700">Posterior</text>
                <text x="249" y="72" text-anchor="middle" font-size="12" fill="#5f7488">ADH</text>
                <text x="249" y="88" text-anchor="middle" font-size="12" fill="#5f7488">Oxytocin</text>

                <rect x="332" y="30" width="146" height="72" rx="10" fill="#eefaf7" stroke="#d4ece4" />
                <text x="405" y="54" text-anchor="middle" font-size="13" fill="#1c564f" font-weight="700">Board focus</text>
                <text x="405" y="72" text-anchor="middle" font-size="12" fill="#5b7a74">Prolactinoma</text>
                <text x="405" y="88" text-anchor="middle" font-size="12" fill="#5b7a74">Acromegaly, DI, SIADH</text>

                <rect x="20" y="128" width="458" height="68" rx="10" fill="#ffffff" stroke="#d8e4f2" />
                <text x="249" y="154" text-anchor="middle" font-size="13" fill="#2a4963" font-weight="700">
                  Strategy is secretion control plus consequence management
                </text>
                <text x="249" y="172" text-anchor="middle" font-size="12" fill="#45637e">
                  Lower excess hormone effects or replace deficient ADH signaling as needed
                </text>
              </svg>
              <p>Tumor control and water-balance correction dominate management questions.</p>
            </div>
          </div>
        </header>

        <section class="section" id="pituitary-physiology">
          <h2>1. Pituitary Physiology (Foundation First)</h2>
          <div class="grid-2">
            <div class="box">
              <h3>Anterior Pituitary Hormones</h3>
              <ul>
                <li>ACTH, TSH, GH, prolactin, LH, FSH</li>
              </ul>
            </div>
            <div class="box">
              <h3>Posterior Pituitary Hormones</h3>
              <ul>
                <li>ADH (vasopressin), oxytocin</li>
              </ul>
            </div>
          </div>
        </section>

        <section class="section" id="prolactinoma">
          <h2>2. Prolactinoma</h2>
          <p>Most common pituitary adenoma.</p>
          <div class="grid-2">
            <div class="box">
              <h3>Pathophysiology and Features</h3>
              <ul>
                <li>Excess prolactin suppresses GnRH and lowers LH/FSH</li>
                <li>Women: galactorrhea, amenorrhea, infertility</li>
                <li>Men: low libido, erectile dysfunction</li>
              </ul>
            </div>
            <div class="box">
              <h3>First-Line Therapy</h3>
              <ul>
                <li>Dopamine agonists: cabergoline, bromocriptine</li>
                <li>MOA: dopamine receptor stimulation inhibits prolactin secretion and shrinks tumor</li>
                <li>Side effects: nausea, orthostatic hypotension, headache</li>
                <li>Caution: uncontrolled hypertension contexts</li>
                <li>Cabergoline is usually preferred for tolerability</li>
              </ul>
            </div>
          </div>
        </section>

        <section class="section" id="acromegaly">
          <h2>3. Acromegaly</h2>
          <div class="grid-2">
            <div class="box">
              <h3>Clinical Pattern</h3>
              <ul>
                <li>Enlarged hands/feet</li>
                <li>Coarse facial features</li>
                <li>Cardiomegaly and glucose dysregulation</li>
              </ul>
            </div>
            <div class="box">
              <h3>Management</h3>
              <ul>
                <li>First-line: surgical resection</li>
                <li>Persistent disease: medical therapy escalation</li>
              </ul>
            </div>
          </div>

          <table class="table">
            <thead>
              <tr>
                <th>Drug</th>
                <th>MOA</th>
                <th>Major Side Effects</th>
                <th>Notes</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td>Somatostatin analogues (octreotide, lanreotide)</td>
                <td>Suppress GH secretion and lower IGF-1</td>
                <td>GI upset, gallstones</td>
                <td>Common post-surgical adjunct class</td>
              </tr>
              <tr>
                <td>Pegvisomant</td>
                <td>GH receptor antagonist blocking peripheral GH action</td>
                <td>Liver enzyme elevation, injection site reactions</td>
                <td>Used when biochemical control remains inadequate</td>
              </tr>
            </tbody>
          </table>
        </section>

        <section class="section" id="diabetes-insipidus">
          <h2>4. Diabetes Insipidus (DI)</h2>
          <div class="grid-2">
            <div class="box">
              <h3>Types and Features</h3>
              <ul>
                <li>Central DI: ADH deficiency</li>
                <li>Nephrogenic DI: renal ADH resistance</li>
                <li>Clinical pattern: polyuria, polydipsia, hypernatremia</li>
              </ul>
            </div>
            <div class="box">
              <h3>Therapy</h3>
              <ul>
                <li>Central DI: desmopressin</li>
                <li>Nephrogenic DI: thiazides plus low-sodium diet</li>
              </ul>
            </div>
          </div>

          <table class="table">
            <thead>
              <tr>
                <th>Drug</th>
                <th>MOA</th>
                <th>Major Side Effects</th>
                <th>Notes</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td>Desmopressin</td>
                <td>ADH analogue acting at V2 receptors to increase collecting-duct water reabsorption</td>
                <td>Hyponatremia, water retention</td>
                <td>Indicated for central DI</td>
              </tr>
              <tr>
                <td>Thiazide diuretics (nephrogenic DI)</td>
                <td>Reduce distal sodium delivery and increase proximal water reabsorption, lowering urine volume</td>
                <td>Hypokalemia, hyponatremia, dehydration risk</td>
                <td>Classic paradoxical urine reduction mechanism</td>
              </tr>
            </tbody>
          </table>
        </section>

        <section class="section" id="siadh">
          <h2>5. SIADH (Syndrome of Inappropriate ADH)</h2>
          <div class="grid-2">
            <div class="box">
              <h3>Pattern and Causes</h3>
              <ul>
                <li>Excess ADH causes water retention and dilutional hyponatremia</li>
                <li>Common causes: small-cell lung cancer, CNS disease, medications</li>
                <li>Labs: low sodium and low serum osmolality</li>
              </ul>
            </div>
            <div class="box">
              <h3>Treatment Strategy</h3>
              <ul>
                <li>Mild/moderate: fluid restriction</li>
                <li>Severe symptomatic hyponatremia: hypertonic saline (careful correction)</li>
                <li>Resistant cases: V2 antagonists such as tolvaptan</li>
              </ul>
            </div>
          </div>

          <div class="box stack">
            <h3>Tolvaptan</h3>
            <ul>
              <li>MOA: V2 receptor antagonism promotes free-water excretion</li>
              <li>Side effects: thirst, hepatotoxicity risk</li>
              <li>Used selectively in difficult or persistent SIADH cases</li>
            </ul>
          </div>
        </section>

        <section class="section" id="management-recap-drill">
          <h2>Management Recap Drill</h2>
          <div class="flow">
            <div class="step"><strong>Prolactinoma:</strong> cabergoline first-line dopamine agonist.</div>
            <div class="arrow" aria-hidden="true">&#8595;</div>
            <div class="step"><strong>Acromegaly:</strong> surgery first, then somatostatin analogue if persistent.</div>
            <div class="arrow" aria-hidden="true">&#8595;</div>
            <div class="step"><strong>Central DI:</strong> desmopressin replacement.</div>
            <div class="arrow" aria-hidden="true">&#8595;</div>
            <div class="step"><strong>Nephrogenic DI:</strong> thiazide-based volume strategy.</div>
            <div class="arrow" aria-hidden="true">&#8595;</div>
            <div class="step"><strong>SIADH:</strong> fluid restriction first, tolvaptan for resistant cases.</div>
          </div>

          <div class="diagram-card">
            <p class="diagram-title">Visual Algorithm Placeholder</p>
            <p>
              [Insert Pituitary Disorder Diagnostic and Treatment Flowchart Here During UI Integration]
            </p>
          </div>
        </section>

        <section class="section refs">
          <h2>Guideline References (Management)</h2>
          <div class="grid-2">
            <div class="box">
              <h3>Endocrine Society Clinical Practice Guidelines</h3>
              <a href="https://www.endocrine.org" target="_blank" rel="noopener">
                https://www.endocrine.org
              </a>
            </div>
            <div class="box">
              <h3>Guideline Scope</h3>
              <ul>
                <li>Hyperprolactinemia management</li>
                <li>Acromegaly treatment escalation</li>
                <li>DI and SIADH management standards</li>
              </ul>
            </div>
          </div>
        </section>

        <section class="section" id="exam-traps">
          <h2>6. Common Exam Traps</h2>
          <div class="stack">
            <div class="callout alert">Cabergoline is preferred first-line for prolactinoma.</div>
            <div class="callout alert">Thiazides can paradoxically reduce urine volume in nephrogenic DI.</div>
            <div class="callout alert">SIADH typically shows low sodium with low serum osmolality.</div>
            <div class="callout alert">Desmopressin treats central DI, not classic nephrogenic DI.</div>
            <div class="callout alert">Pegvisomant blocks GH receptor effects rather than GH secretion.</div>
          </div>
        </section>

        <section class="section" id="quick-revision">
          <h2>7. Quick Revision Summary</h2>
          <div class="grid-2">
            <div class="box">
              <h3>Must Remember</h3>
              <ul>
                <li>Pituitary acts as a master endocrine regulator</li>
                <li>Prolactinoma responds to dopamine agonists</li>
                <li>Acromegaly often starts with surgical control</li>
                <li>DI reflects inadequate ADH effect</li>
                <li>SIADH reflects excessive ADH effect</li>
              </ul>
            </div>
            <div class="box">
              <h3>Practice Questions Placeholder</h3>
              <ul>
                <li>Topic: Pituitary Disorders</li>
                <li>
                  Subtopics: prolactinoma, acromegaly, diabetes insipidus,
                  SIADH, vasopressin antagonists
                </li>
              </ul>
            </div>
          </div>
        </section>
      </article>
    </div>
  </body>
</html>
